Retatrutide

Retatrutide (LY3437943) is a 39-residue single-molecule triagonist of the GIP, GLP-1, and glucagon receptors developed by Eli Lilly. The peptide carries a C20 fatty diacid Lys17 acylation for albumin binding and Aib substitutions for protease resistance. Reported in 2023 NEJM Phase 2 results.

• Retatrutide Structure and Synthesis for Laboratory Use
• How to Evaluate Retatrutide COAs: HPLC and Mass Spectrometry Explained
• Retatrutide Stability, Solubility and Storage for Research
• Retatrutide vs Semaglutide – Research Comparison
• Retatrutide Key Preclinical Research Findings Summary
• Retatrutide Analytical Testing Methods: Deep Dive

≥99% purity, third-party COA verified, manufactured in the USA. For research use only — not for human or veterinary use.